BMRN

BioMarin Pharmaceutical Inc. NASDAQ

Healthcare ·Biotechnology ·US · biomarin.com

$54.06

After hrs $55.00 -0.83%

Mkt Cap $10.7B

52w Low $50.76 21.3% of range 52w High $66.28

50d MA $57.25 200d MA $56.40

P/E (TTM) 29.7x

EV/EBITDA 18.7x

P/B 1.7x

Debt/Equity 0.1x

ROE 5.7%

P/FCF 15.7x

RSI (14) —

ATR (14) —

Beta 0.29

50d MA $57.25

200d MA $56.40

Avg Volume 2.0M

About

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS … BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 23, 2026	AMC	0.17	-0.24	-241.7%	62.92	-4.2%	-0.5%	-2.4%	-2.9%	-1.9%	-5.1%	-11.6%	—
Oct 27, 2025	AMC	-0.15	0.12	+180.0%	52.67	+1.4%	+1.6%	-1.5%	-1.4%	+1.7%	+0.3%	+5.4%	—
Aug 4, 2025	AMC	0.86	1.44	+67.2%	60.31	+5.0%	+2.7%	+0.6%	-1.4%	-4.9%	-5.8%	-2.2%	—
May 1, 2025	AMC	0.94	1.13	+20.2%	62.71	+2.5%	-1.1%	-1.0%	-4.9%	-5.4%	-4.6%	-9.0%	—
Feb 19, 2025	AMC	0.54	0.92	+70.4%	65.61	+6.7%	+4.8%	+4.0%	+5.2%	+8.5%	+4.9%	+8.6%	—
Oct 29, 2024	AMC	0.78	0.91	+16.7%	69.91	-0.3%	-4.6%	-5.8%	-4.7%	-5.6%	-5.5%	-5.5%	—
Aug 5, 2024	AMC	0.36	0.96	+168.3%	80.47	+9.1%	+8.0%	+7.2%	+9.2%	+10.2%	+10.6%	+11.7%	—
Apr 24, 2024	AMC	0.31	0.71	+127.7%	91.20	-5.4%	-9.9%	-11.3%	-9.9%	-11.4%	-8.6%	-17.2%	—
Feb 22, 2024	AMC	0.44	0.49	+11.4%	89.97	+1.1%	+1.4%	+0.1%	+0.8%	-1.7%	-4.1%	-3.8%	—
Nov 1, 2023	AMC	0.46	0.46	+0.0%	84.01	-3.6%	-5.2%	-5.3%	-9.3%	+1.8%	+1.8%	+10.0%	—
Jul 31, 2023	AMC	0.47	0.54	+14.9%	87.93	-1.1%	+1.2%	+0.5%	-0.2%	+0.7%	-0.1%	+6.7%	—
Apr 26, 2023	AMC	0.43	0.60	+39.5%	93.00	-1.0%	-0.6%	+3.3%	+4.3%	+0.9%	+0.6%	-4.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 27	Morgan Stanley	Reiterates	Overweight	$120	$53.18	$53.69	+1.0%	+1.2%	+0.2%	+1.9%	+1.4%	+1.7%
Mar 11	BofA Securities	Maintains	Buy → Buy	—	$60.89	$60.18	-1.2%	-0.9%	-3.0%	-3.9%	-5.7%	-7.9%
Mar 4	Barclays	Maintains	Overweight → Overweight	—	$58.53	$59.00	+0.8%	+3.2%	+3.5%	+4.4%	+4.0%	+4.0%
Mar 2	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$61.73	$60.71	-1.7%	-3.2%	-5.2%	-2.1%	-1.9%	-1.0%
Mar 2	Freedom Broker	Maintains	Buy → Buy	—	$61.73	$60.71	-1.7%	-3.2%	-5.2%	-2.1%	-1.9%	-1.0%
Feb 26	Canaccord Genuity	Maintains	Buy → Buy	—	$61.44	$61.36	-0.1%	-0.5%	+0.5%	-2.8%	-4.7%	-1.6%
Feb 25	Bernstein	Maintains	Outperform → Outperform	—	$62.62	$62.14	-0.8%	-1.9%	-2.4%	-1.4%	-4.6%	-6.5%
Feb 25	Guggenheim	Maintains	Buy → Buy	—	$62.62	$62.14	-0.8%	-1.9%	-2.4%	-1.4%	-4.6%	-6.5%
Feb 25	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$62.62	$62.14	-0.8%	-1.9%	-2.4%	-1.4%	-4.6%	-6.5%
Feb 24	Oppenheimer	Maintains	Outperform → Outperform	—	$62.92	$60.30	-4.2%	-0.5%	-2.4%	-2.9%	-1.9%	-5.1%
Feb 18	Wells Fargo	Maintains	Overweight → Overweight	—	$59.95	$60.08	+0.2%	+3.1%	+5.8%	+6.9%	+5.0%	+4.5%
Feb 6	Piper Sandler	Maintains	Overweight → Overweight	—	$57.15	$57.26	+0.2%	+1.7%	+1.2%	+4.4%	+5.5%	+4.9%
Jan 20	Canaccord Genuity	Upgrade	Hold → Buy	—	$54.59	$54.73	+0.3%	+3.2%	+4.0%	+4.7%	+3.0%	+4.0%
Dec 23	Truist	Maintains	Buy → Buy	—	$59.28	$59.59	+0.5%	+3.1%	+1.5%	+1.1%	+1.3%	-0.5%
Dec 22	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$61.15	$60.59	-0.9%	-3.1%	-0.0%	-1.6%	-2.0%	-1.8%
Dec 3	Leerink Partners	Downgrade	Outperform → Market Perform	—	$53.89	$53.52	-0.7%	+0.8%	-0.1%	-0.9%	-1.1%	-0.3%
Nov 6	Stifel	Downgrade	Buy → Hold	—	$52.80	$52.03	-1.5%	-1.8%	-2.5%	-0.2%	+4.0%	+4.8%
Nov 3	Freedom Broker	Maintains	Buy → Buy	—	$53.57	$53.03	-1.0%	-1.3%	-2.0%	-1.4%	-3.2%	-3.9%
Nov 3	Bernstein	Maintains	Outperform → Outperform	—	$53.57	$53.03	-1.0%	-1.3%	-2.0%	-1.4%	-3.2%	-3.9%
Oct 28	Morgan Stanley	Maintains	Overweight → Overweight	—	$52.67	$53.40	+1.4%	+1.6%	-1.5%	-1.4%	+1.7%	+0.3%
Oct 28	Truist	Maintains	Buy → Buy	—	$52.67	$53.40	+1.4%	+1.6%	-1.5%	-1.4%	+1.7%	+0.3%
Oct 28	Barclays	Maintains	Overweight → Overweight	—	$52.67	$53.40	+1.4%	+1.6%	-1.5%	-1.4%	+1.7%	+0.3%
Oct 28	Wells Fargo	Maintains	Overweight → Overweight	—	$52.67	$53.40	+1.4%	+1.6%	-1.5%	-1.4%	+1.7%	+0.3%
Oct 28	Stifel	Maintains	Buy → Buy	—	$52.67	$53.40	+1.4%	+1.6%	-1.5%	-1.4%	+1.7%	+0.3%
Oct 27	HC Wainwright & Co.	Maintains	Neutral → Neutral	—	$54.48	$54.98	+0.9%	-3.3%	-1.8%	-4.8%	-4.7%	-1.7%
Oct 9	JP Morgan	Maintains	Overweight → Overweight	—	$54.69	$55.39	+1.3%	-1.5%	-4.3%	-4.1%	-4.1%	-2.9%
Aug 6	Guggenheim	Maintains	Buy → Buy	—	$61.93	$61.58	-0.6%	-2.0%	-4.0%	-7.4%	-8.3%	-8.2%
Aug 5	UBS	Maintains	Buy → Buy	—	$60.31	$63.34	+5.0%	+2.7%	+0.6%	-1.4%	-4.9%	-5.8%
Jul 22	Morgan Stanley	Maintains	Overweight → Overweight	—	$56.56	$56.81	+0.4%	+4.7%	+5.5%	+5.7%	+4.3%	+2.8%
Jul 14	JP Morgan	Maintains	Overweight → Overweight	—	$58.10	$58.06	-0.1%	+0.2%	-2.5%	+0.5%	+0.5%	-1.4%
May 5	Goldman Sachs	Maintains	Buy → Buy	—	$62.03	$61.83	-0.3%	+0.0%	-3.9%	-4.4%	-3.6%	-5.1%
May 2	Citigroup	Maintains	Neutral → Neutral	—	$62.71	$64.26	+2.5%	-1.1%	-1.0%	-4.9%	-5.4%	-4.6%
Feb 24	Oppenheimer	Upgrade	Perform → Outperform	—	$68.25	$68.38	+0.2%	+1.1%	+4.3%	+0.8%	+1.3%	+4.3%
Feb 20	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$65.61	$70.00	+6.7%	+4.8%	+4.0%	+5.2%	+8.5%	+4.9%
Feb 20	UBS	Maintains	Buy → Buy	—	$65.61	$70.00	+6.7%	+4.8%	+4.0%	+5.2%	+8.5%	+4.9%
Feb 20	BofA Securities	Maintains	Buy → Buy	—	$65.61	$70.00	+6.7%	+4.8%	+4.0%	+5.2%	+8.5%	+4.9%
Feb 20	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$65.61	$70.00	+6.7%	+4.8%	+4.0%	+5.2%	+8.5%	+4.9%
Feb 20	Scotiabank	Maintains	Sector Perform → Sector Perform	—	$65.61	$70.00	+6.7%	+4.8%	+4.0%	+5.2%	+8.5%	+4.9%
Feb 20	Citigroup	Maintains	Neutral → Neutral	—	$65.61	$70.00	+6.7%	+4.8%	+4.0%	+5.2%	+8.5%	+4.9%
Feb 20	Piper Sandler	Maintains	Overweight → Overweight	—	$65.61	$70.00	+6.7%	+4.8%	+4.0%	+5.2%	+8.5%	+4.9%
Dec 12	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$65.97	$65.45	-0.8%	+0.4%	+0.1%	-0.7%	+1.8%	-1.9%
Oct 30	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$69.91	$69.67	-0.3%	-4.6%	-5.8%	-4.7%	-5.6%	-5.5%
Oct 30	William Blair	Downgrade	Outperform → Market Perform	—	$69.91	$69.67	-0.3%	-4.6%	-5.8%	-4.7%	-5.6%	-5.5%
Oct 30	Baird	Maintains	Neutral → Neutral	—	$69.91	$69.67	-0.3%	-4.6%	-5.8%	-4.7%	-5.6%	-5.5%
Oct 30	Canaccord Genuity	Maintains	Hold → Hold	—	$69.91	$69.67	-0.3%	-4.6%	-5.8%	-4.7%	-5.6%	-5.5%
Oct 30	JP Morgan	Maintains	Overweight → Overweight	—	$69.91	$69.67	-0.3%	-4.6%	-5.8%	-4.7%	-5.6%	-5.5%
Oct 30	Evercore ISI	Maintains	Outperform → Outperform	—	$69.91	$69.67	-0.3%	-4.6%	-5.8%	-4.7%	-5.6%	-5.5%
Oct 30	Citigroup	Maintains	Neutral → Neutral	—	$69.91	$69.67	-0.3%	-4.6%	-5.8%	-4.7%	-5.6%	-5.5%
Oct 30	UBS	Maintains	Buy → Buy	—	$69.91	$69.67	-0.3%	-4.6%	-5.8%	-4.7%	-5.6%	-5.5%
Oct 30	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$69.91	$69.67	-0.3%	-4.6%	-5.8%	-4.7%	-5.6%	-5.5%